News Releases

-- PLx to focus on commercialization of Aspertec -- HOUSTON , April 19, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products: Aspertec 325 mg and Aspertec 81 mg (referred to together as

HOUSTON, Feb. 14, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (PLx), a late-stage specialty pharmaceutical company developing next-generation nonsteroidal anti-inflammatory drugs and other pharmaceutical agents today announced that

NEW YORK and HOUSTON, Dec. 22, 2016 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (NASDAQ:  DPRX ) and PLx Pharma Inc.

HOUSTON (January 4, 2016) – PLx Pharma Inc. (PLx), a privately-held, late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide safer and more effective aspirin products, announces that Natasha Giordano has been appointed as  ...

Relative contributions of local and systemic mechanisms of upper gastrointestinal (GI) injury following aspirin are unknown. Studies suggest that aspirin’s GI risk is age related and that gastroprotection may be needed at therapy initiation.

Background Chronic use of NSAIDs is associated with gastrointestinal (GI) toxicity that increases with age. Aim To evaluate the GI safety and therapeutic efficacy of ibuprofen chemically associated with phosphatidylcholine (PC) in osteoarthritic (OA) patients.